Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rain Oncology Inc (RAIN)

Rain Oncology Inc (RAIN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Rain Oncology Inc 8000 Jarvis Avenue Suite 204 Newark CA 94560 USA

www.rainoncology.com P: 510-953-5559

Description:

Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.

Key Statistics

Overview:

Market Capitalization, $K 44,015
Enterprise Value, $K -17,945
Shares Outstanding, K 36,376
Annual Sales, $ 0 K
Annual Net Income, $ -75,720 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -7,030 K
EBIT, $ -76,610 K
EBITDA, $ -76,860 K
60-Month Beta 0.27
% of Insider Shareholders 17.40%
% of Institutional Shareholders 65.84%
Float, K 30,047
% Float 82.60%
Short Volume Ratio 0.43

Growth:

1-Year Return -87.28%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.19 on 11/09/23
Next Earnings Date 03/14/24
Earnings Per Share ttm -2.06
EPS Growth vs. Prev Qtr 68.85%
EPS Growth vs. Prev Year 72.06%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RAIN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -82.96%
Return-on-Assets % -68.31%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.65
Book Value/Share 1.86
Interest Coverage -3.81
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar